Abstract
Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activator (alteplase, rt-PA), however, alteplase is substantially underused because of concerns regarding adverse bleeding risk. This limitation has fuelled the search for other thrombolytic agents, which display greater fibrin dependence and selectivity, but lack detrimental effects within the central nervous system. Development of alternative fibrinolytic agents that might be easier and safer to administer could lead to wider acceptance and use of thrombolytic therapy for stroke. Although other thrombolytic agents (e.g. streptokinase) have failed to show benefit over alteplase, there is still on-going research in search of alternative agents with higher target specificity and better safety profile. The potential thrombolytic agents with trials in progress include desmoteplase, tenecteplase, reteplase, plasmin and microplasmin. This review summarises current therapies with thrombolytics (e.g. alteplase and urokinase), their limitations and side effects, and also discusses ongoing clinical studies with the various potential emerging thrombolytic agents.
Keywords: Ischaemic stroke, thrombolytics, plasminogen activators, direct fibrinolytics, thrombolysis.
CNS & Neurological Disorders - Drug Targets
Title:Thrombolytic Agents for Acute Ischaemic Stroke Treatment: The Past, Present and Future
Volume: 12 Issue: 2
Author(s): Joyce S. Balami, Ruoli Chen, Brad A. Sutherland and Alastair M. Buchan
Affiliation:
Keywords: Ischaemic stroke, thrombolytics, plasminogen activators, direct fibrinolytics, thrombolysis.
Abstract: Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activator (alteplase, rt-PA), however, alteplase is substantially underused because of concerns regarding adverse bleeding risk. This limitation has fuelled the search for other thrombolytic agents, which display greater fibrin dependence and selectivity, but lack detrimental effects within the central nervous system. Development of alternative fibrinolytic agents that might be easier and safer to administer could lead to wider acceptance and use of thrombolytic therapy for stroke. Although other thrombolytic agents (e.g. streptokinase) have failed to show benefit over alteplase, there is still on-going research in search of alternative agents with higher target specificity and better safety profile. The potential thrombolytic agents with trials in progress include desmoteplase, tenecteplase, reteplase, plasmin and microplasmin. This review summarises current therapies with thrombolytics (e.g. alteplase and urokinase), their limitations and side effects, and also discusses ongoing clinical studies with the various potential emerging thrombolytic agents.
Export Options
About this article
Cite this article as:
Balami Joyce S., Chen Ruoli, Sutherland Brad A. and Buchan Alastair M., Thrombolytic Agents for Acute Ischaemic Stroke Treatment: The Past, Present and Future, CNS & Neurological Disorders - Drug Targets 2013; 12 (2) . https://dx.doi.org/10.2174/18715273113129990057
DOI https://dx.doi.org/10.2174/18715273113129990057 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Positive and Negative Effects of TGF-β Signaling Pathways in Carcinogenesis
Current Signal Transduction Therapy Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine
Current Medicinal Chemistry Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Medicinal Chemistry of 2,2,4-Substituted Morpholines
Current Medicinal Chemistry Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Current Gene Therapy Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Antimalarials: Molecular Drug Targets and Mechanism of Action
Current Topics in Medicinal Chemistry Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Current Enzyme Inhibition Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Anti-hyperglycemic Potential of Natural Products
Mini-Reviews in Medicinal Chemistry Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Current Medicinal Chemistry - Anti-Cancer Agents Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Anticoagulant Therapy in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews